Buyout Desk
Add-on

EQT-backed Dechra acquires Gallant Pet

The San Diego company develops cell therapies for companion animals. Dechra completed the acquisition on November 17.

Target
Gallant Pet
Acquirer
Dechra
Backed by
EQT
Status
Completed
Announced
Closed

Dechra agreed to acquire Gallant Pet on November 9 and completed the purchase on November 17. Gallant is an animal health biotechnology company developing ready-to-use regenerative therapies for pets. Terms were confidential.

Gallant was founded in 2018 and operates a manufacturing facility in San Diego, California. Dechra said the deal expands its veterinary specialty care business into regenerative medicine. Sidley represented Dechra.

EQT lists Dechra as a current portfolio company. EQT and co-investors took Dechra private in 2024.

Background

Business
Companion animal therapeutics developer
Deal type
Add-on
Headquarters
San Diego, California
Advisers

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.

EQT deal history